With lessons learned from Vor, Siddhartha Mukherjee takes a different route to target solid tumors with startup Myeloid

Conner Mitchell

Siddhartha Mukherjee is a busy man these days.

The Pulitzer Prize-winning author, Columbia professor, oncologist, hematologist and leading cancer researcher in 2016 launched Vor, a Cambridge, MA-based startup focused on a new cancer treatment in which cell surface antigens such as CD33 are removed from hematopoietic stem cells. They can then unleash a CAR-T therapy — made from T cells in a patient’s blood and genetically engineered to hunt for the antigens — to treat cancer using the body’s own immune system without attacking healthy cells that would’ve shared those antigens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

With lessons learned from Vor, Siddhartha Mukherjee takes a different route to target solid tumors with startup Myeloid

Conner Mitchell

Unlock this article instantly by becoming a free subscriber.

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

With lessons learned from Vor, Sid­dhartha Mukher­jee takes a dif­fer­ent route to tar­get sol­id tu­mors with start­up Myeloid

Conner Mitchell

Unlock this article instantly by becoming a free subscriber.

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

With lessons learned from Vor, Siddhartha Mukherjee takes a different route to target solid tumors with startup Myeloid

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy